Moreover, inflammatory markers such as IL-10 and GRO increased significantly in hospitalized COVID-19 patients (Savarraj et al., 2021), which will result in worse situations if these patients were treated with a high dose of CQ. The gene discussed is CXCL1; the disease is COVID-19.